Long-acting risperidone: a review of its use in schizophrenia.
about
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulationLong-acting risperidone: a review of its role in the treatment of bipolar disorder.Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Extended release drug delivery strategies in psychiatry: theory to practiceAccelerated polymer biodegradation of risperidone poly(D, L-lactide-co-glycolide) microspheresPharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Risperidone: a review.Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.A review of paliperidone palmitate.Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.Understanding depot antipsychotics: an illustrated guide to kinetics.Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.Design and synthesis of (5-amino-1, 2, 4-triazin-6-yl)(2-(benzo[d] isoxazol-3-yl) pyrrolidin-1-yl)methanone derivatives as sodium channel blocker and anticonvulsant agents.Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics.Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.Experience with risperidone long-acting injection: results of a naturalistic observation study.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.Monographs on drugs which are frequently analyzed in therapeutic drug monitoring / Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werdenEnhanced Degradation of Lactide-co-Glycolide Polymer with Basic Nucleophilic Drugs
P2860
Q33235110-F52524FD-C3B0-45B2-8F4B-1B2A4ADA3FA6Q33826308-E86ABDE9-C081-46C5-942E-AE1241BDBA7BQ33886093-B2415494-B8BC-4040-AA4B-53DE50C6E86AQ33902253-D635A6F9-322D-419B-B5CB-A3E58A36704DQ34315836-260A3DAA-3CE1-472E-A87E-031CCBD27CC1Q34396625-E2B03C2F-2A8F-4F82-B02B-494BD6877EB3Q34454729-C77C1285-2430-4915-991D-FE391C42DAA7Q34922985-35FD5037-77C7-4C06-816F-116266BD830DQ36150794-04E9F1F2-05E0-4367-8512-3FD9260DA4ACQ36370291-D6957A4D-3C49-46AC-9684-5BF4F60B2128Q38067137-8169868F-089F-4A4A-8170-69E2A83E8E96Q38094683-F22F81D7-A801-4F72-A15D-F9DA7EB84D5DQ38115487-C7080CF1-DD86-41D2-B2B1-C4E39D0E45FEQ38125213-81395A2F-D5E9-491F-B0DC-A41276EC9E50Q42279135-A34CC011-3BA9-4B45-9E2A-89FB0323E70EQ43107438-2C2239E1-D72E-4B5A-9B28-D7CAFAEAC9BDQ45769368-BE94E243-1E48-446F-BCDF-BF4BC3A2B1DAQ46896761-6C1BAAD7-861D-44A1-819A-3953E7C04D59Q46896765-1897948B-AA6B-4058-8A26-37DC0E2C9C63Q47860209-5D76E01B-F155-401C-AF8E-10C69F704803Q48414001-64A397EB-7CB8-42C3-A3AB-656F89580446Q51502306-C158A526-A3CA-41B3-9B8F-CEB6AAB98231Q51908469-8E2FF41B-54AB-439B-B5C9-ED26BC2CD215Q54217848-71E9A81B-6660-4709-A657-464484505A95Q57550218-2A851646-047A-4F56-8566-F2B00364D9CAQ59103165-4D55F38C-A829-4D5C-A2D7-3903A94A3854
P2860
Long-acting risperidone: a review of its use in schizophrenia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Long-acting risperidone: a review of its use in schizophrenia.
@ast
Long-acting risperidone: a review of its use in schizophrenia.
@en
type
label
Long-acting risperidone: a review of its use in schizophrenia.
@ast
Long-acting risperidone: a review of its use in schizophrenia.
@en
prefLabel
Long-acting risperidone: a review of its use in schizophrenia.
@ast
Long-acting risperidone: a review of its use in schizophrenia.
@en
P1433
P1476
Long-acting risperidone: a review of its use in schizophrenia.
@en
P2093
Karen L Goa
Tracy Swainston Harrison
P304
P356
10.2165/00023210-200418020-00005
P577
2004-01-01T00:00:00Z
P6179
1011492369